Accelerating the Elimination of Cervical Cancer: Innovation, Partnership, and Accessible Screening
During HPV Prevention Week in Canada, the national health campaign #CANADAvsHPV brings renewed focus to a critical reality: cervical cancer is one of the most preventable forms of cancer. With Canada working toward the target of eliminating cervical cancer by 2040, advancing diagnostic precision and broadening access to screening are paramount.
Demystifying HPV and Cancer Prevention
Cervical cancer prevention has evolved dramatically as we better understand its root cause. High-risk types of the Human Papillomavirus (HPV) cause nearly all cervical cancer cases.
"Scientists proved that eliminating the virus prevents the cancer. Because high-risk HPV is the underlying cause, identifying its presence early gives clinicians the precise insight needed to intervene long before high-grade precancerous lesions develop." — Dr. François Coutlée
Despite its prevalence, HPV carries unnecessary stigma. The virus is extremely common and typically asymptomatic. Shifting clinical focus toward direct HPV primary screening allows healthcare systems to target the root cause directly, replacing traditional Pap smears with high-precision molecular diagnostic tools. In 2026, while the majority of Canadian provinces have transitioned to offering HPV primary screening, significant challenges remain regarding accessibility and implementation within provincial healthcare systems, particularly in rural, remote, and indigenous communities
30 Years of Diagnostic Progress: The Power of Honest Collaboration & Partnership
Modern diagnostic capabilities result from decades of continuous technological refinement.
"If you go back to 1987, testing required manually moving test tubes every minute into hot water baths. Today, automated laboratories process samples with incredible speed, standardization, and precision." — Dr. François Coutlée
This evolution relies on collaborative research between health care professionals, academic medical centers, and industry. Open feedback from clinicians—highlighting where early methods fell short—has directly guided the development of robust, peer-reviewed assays designed for everyday clinical workflows.
Expanding Access Through Self-Collection
Achieving national elimination goals requires closing preventative care gaps and reaching under-screened populations. Advances in vaginal self-collection methods allow individuals to privately collect their own samples, overcoming logistical and personal barriers to traditional clinic visits.
By combining advanced molecular testing with flexible screening options, Roche Canada remains committed to supporting clinicians, researchers, and public health initiatives in the shared mission to eliminate cervical cancer.
For more information on HPV testing in Canada, please visit Roche’s Sexually Transmitted Infections and HPV Assays page, contact us at [email protected], or complete our inquiry form.